Lucha 1997.
Study characteristics | |||
Patient sampling |
Country USA Study design Retrospective Setting Hospital Dates of data collection 1981 ‐ 1985 Population (n) N/R Inclusion criteria Newly diagnosed colorectal cancer undergoing operative resection for cure (Astler Coller A,B,C) Exclusion criteria Metastatic disease and synchronous cancers Participants Included (n) 285 |
||
Patient characteristics and setting |
Age range 66.8 (range, 31 ‐ 96) Smoking status N/R Site of primary tumour Colorectal Stage of primary tumour Astler‐Coller Stage A 39, B1 57, B2 109, C1 15, C2 60 Perioperative investigations done to ensure no residual disease Intraoperative criteria for curative resection included absence of gross residual disease Chemotherapy/radiotherapy? No Recurrences (n) 66 Site of recurrences N/R |
||
Index tests |
CEA timing 2‐monthly for 2 years, 3‐monthly for year 3, 6‐monthly for years 4 ‐ 5, annually afterwards. A repeat CEA was performed in patients who had an abnormal rise CEA technique Abbott CEA threshold 5 µg/L Definition of positive 2 consecutive samples Which CEA value (s) used? At time of recurrence |
||
Target condition and reference standard(s) |
Follow‐up schedule 2 monthly for 2 years, 3 monthly for year 3, 6 monthly for years 4 and 5, annually afterwards. A detailed history and physical examination was performed, and CEA levels were monitored at each encounter. Reference standard Two successive CEA elevations were investigated with diagnostic imaging and / or endoscopy when indicated. |
||
Flow and timing |
Timing of CEA vs reference standard (days) per protocol |
||
Comparative | |||
Notes | |||
Methodological quality | |||
Item | Authors' judgement | Risk of bias | Applicability concerns |
DOMAIN 1: Patient Selection | |||
Was a consecutive or random sample of patients enrolled? | Yes | ||
Did the study avoid inappropriate exclusions? | Yes | ||
Low | Low | ||
DOMAIN 2: Index Test All CEA thresholds | |||
If a threshold was used, was it pre‐specified? | Yes | ||
Is the same method and instrument used for all CEA measurements? | Yes | ||
Is there an estimation of reproducibility of the method, for example the % coefficient of variation at specific concentrations? | No | ||
Is there an indication of method accuracy, for example, is there evidence of participation in an external quality assessment and proficiency testing scheme? | No | ||
Low | Low | ||
DOMAIN 3: Reference Standard | |||
Is the reference standards likely to correctly classify the target condition? | Yes | ||
Were the reference standard results interpreted without knowledge of the results of the index tests? | No | ||
Low | Unclear | ||
DOMAIN 4: Flow and Timing | |||
Did all patients receive the same reference standard? | No | ||
Were all patients included in the analysis? | Yes | ||
Was the index test repeated prior to the reference standard? | No | ||
Was the the timing between index test(s) and reference standard ascertainable? | Yes | ||
Did all patients receive a reference standard? | No | ||
High |